| Followers | 36 |
| Posts | 11712 |
| Boards Moderated | 0 |
| Alias Born | 02/26/2016 |
Monday, September 22, 2025 10:12:15 AM
How is it that the idea that CS2 is in effect a disaster for certain people?
It is the NORMAL procedural point in the EMA MAA approval process.
IF the WGT crowd wants to put a number out there for approval, the
probability that Anavex IS IN CS2 is higher.
The same attitude is quizzical when outright approval has morphed into
whether a P3 is really a P4 and is of no consequence to the faithful.
The missteps of Missling over 10+ years are numerous, but this CS2 is not one.
An inability to be prepared for and straightforward in response to the LoOI is crucial.
Chill folks. Make sure your dry powder bunker is leak proof.
IF the Holidays finally deliver that shiny bicycle some cite, will $10 buys really matter?
I am tired, however of trying to catch falling knives
Reminds me of the culture shock first time visiting Petworth Cigars in DC.
A normal $20 stick was $40, but I got to watch the people walk by.
This MB is about as polarized as the Genpub so seemingly the vitriol is not unusual.
I still say 40% here will be silent when CHMP speaks and EMA answers.
A few will just chalk it up to process and performance.
The Market WILL fill in that scorecard.
In the short term....I trust Anavex will not find it necessary to ask for an extension in 26 days.
It is the NORMAL procedural point in the EMA MAA approval process.
IF the WGT crowd wants to put a number out there for approval, the
probability that Anavex IS IN CS2 is higher.
The same attitude is quizzical when outright approval has morphed into
whether a P3 is really a P4 and is of no consequence to the faithful.
The missteps of Missling over 10+ years are numerous, but this CS2 is not one.
An inability to be prepared for and straightforward in response to the LoOI is crucial.
Chill folks. Make sure your dry powder bunker is leak proof.
IF the Holidays finally deliver that shiny bicycle some cite, will $10 buys really matter?
I am tired, however of trying to catch falling knives
Reminds me of the culture shock first time visiting Petworth Cigars in DC.
A normal $20 stick was $40, but I got to watch the people walk by.
This MB is about as polarized as the Genpub so seemingly the vitriol is not unusual.
I still say 40% here will be silent when CHMP speaks and EMA answers.
A few will just chalk it up to process and performance.
The Market WILL fill in that scorecard.
In the short term....I trust Anavex will not find it necessary to ask for an extension in 26 days.
Recent AVXL News
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
- Anavex Life Sciences Reports Fiscal 2026 First Quarter Financial Results and Provides Business Update • GlobeNewswire Inc. • 02/09/2026 12:30:00 PM
- Anavex Life Sciences to Announce Fiscal 2026 First Quarter Financial Results on Monday, February 9, 2026 • GlobeNewswire Inc. • 02/03/2026 12:30:00 PM
- Anavex Joins ACCESS-AD, a Major Initiative Funded by the European Commission, Through the Clinical Evaluation of Blarcamesine as Part of a Precision Medicine Approach in Alzheimer’s Disease • GlobeNewswire Inc. • 01/13/2026 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/09/2026 10:26:26 PM
- Edelson Lechtzin LLP Announces an Investigation of Anavex Life Sciences Corp. (NASDAQ: AVXL) and Encourages Investors with Substantial Losses Contact the Firm • PR Newswire (US) • 01/09/2026 01:13:00 AM
- Anavex Life Sciences Appoints Senior Vice President Global Head of Neurology • GlobeNewswire Inc. • 01/08/2026 12:30:00 PM
- Anavex Life Sciences Receives FDA Feedback on Alzheimer’s Disease Program • GlobeNewswire Inc. • 01/06/2026 12:30:00 PM
- Anavex Life Sciences Submitted Request for EMA to Re-Examine Its Opinion • GlobeNewswire Inc. • 12/18/2025 12:30:00 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 12/12/2025 09:05:00 PM
